The First Clinical Medical College, Wenzhou Medical University, Wenzhou, China.
Department of Respiratory and Critical Care Medicine, The 903rd Hospital of PLA, Hangzhou, China.
J Drug Target. 2021 Dec;29(10):1111-1117. doi: 10.1080/1061186X.2021.1927054. Epub 2021 May 26.
It has been reported that clustered miRNAs can be transcribed coordinately and exhibit similar functions by regulating the same targets. miR-1/133a and miR-206/133b are well-characterized miRNA clusters. However, the effect of these clusters on EGFR-TKI resistance is not clear. In this study, we demonstrated that lentivirus-mediated HGF overexpression was able to induce gefitinib resistance in non-small cell lung cancers with EGFR sensitive mutations. miR-1/133a and miR-206/133b clusters could overcome HGF induced gefitinib resistance. Furthermore, the clusters were more effective than individual miRNA. Transcriptome RNA sequencing and bioinformatics analysis revealed that multiple pathways, including 'EGFR tyrosine kinase inhibitor resistance' pathway, were involved in anti-resistance mechanisms of miR-1/133a and miR-206/133b clusters. Western blotting results confirmed the inhibitory effect of miRNA clusters on MET expression and downstream pathway activation. In conclusion, miR-1/133a and miR-206/133b clusters are able to exhibit the synergetic effect on overcoming HGF-induced gefitinib resistance in NSCLC and the mechanisms are through targeting multiple genes related to gefitinib resistance.
据报道,簇状 miRNA 可以通过调节相同的靶标协调转录,并表现出相似的功能。miR-1/133a 和 miR-206/133b 是两个特征明确的 miRNA 簇。然而,这些簇对 EGFR-TKI 耐药的影响尚不清楚。在本研究中,我们证明了慢病毒介导的 HGF 过表达能够诱导具有 EGFR 敏感突变的非小细胞肺癌对吉非替尼产生耐药性。miR-1/133a 和 miR-206/133b 簇可以克服 HGF 诱导的吉非替尼耐药性。此外,这些簇比单个 miRNA 更有效。转录组 RNA 测序和生物信息学分析显示,多种途径,包括“EGFR 酪氨酸激酶抑制剂耐药”途径,参与了 miR-1/133a 和 miR-206/133b 簇的抗耐药机制。Western blotting 结果证实了 miRNA 簇对 MET 表达和下游通路激活的抑制作用。总之,miR-1/133a 和 miR-206/133b 簇能够在非小细胞肺癌中表现出协同作用,克服 HGF 诱导的吉非替尼耐药,其机制是通过靶向与吉非替尼耐药相关的多个基因。